Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)

NCT ID: NCT06467435

Last Updated: 2025-11-26

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-11-06
• Study Completion Date: 2027-08-31

Brief Summary

The study is comprised of two cohorts. Cohort 1 will examine pharmacokinetics of K9 in 3 healthy volunteers over 24 hours. This cohort has been completed. Cohort 2 will involve up to 10 patients with TED. Patients will receive oral K9 BID for up to 24 weeks and will be followed up to a total of 26 weeks with a primary endpoint of safety.

Conditions

Thyroid Eye Disease

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Patients with Thyroid Eye Disease (TED)

Participants receive a regimen of 96 mg tablets of K9 twice a day for 24 weeks

Group Type: EXPERIMENTAL

Kamuvudine-9

Intervention Type: DRUG

96 mg tablets taken twice a day for 24 weeks

Healthy Volunteers

Participants receive one dose of 96 mg tablets of K9 based on weight

Group Type: EXPERIMENTAL

Kamuvudine-9

Intervention Type: DRUG

96 mg tablets taken once

Interventions

Kamuvudine-9

96 mg tablets taken twice a day for 24 weeks

Intervention Type: DRUG

Kamuvudine-9

96 mg tablets taken once

Intervention Type: DRUG

Other Intervention Names

K9; K9

Eligibility Criteria

Inclusion Criteria

Cohort 1

• Subject is willing and able to receive treatment and complete corresponding assessments as required by the protocol

Cohort 2

• Diagnosed with Thyroid Eye Disease (TED).
• Symptomatic TED diagnosed no more than 9 months earlier.
• Clinical Activity Score ≥ 3 (on 7 point scale) for the worse eye.
• Subject is willing and able to receive treatment and complete corresponding assessments as required by the protocol.

Exclusion Criteria

Cohort 1

• Body weight less than 55 kg.
• History of any clinically significant medical disorders the principal investigator considers exclusionary, including (but not limited to), neuromuscular, hematological disease, immune deficiency state, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease.
• Females who are pregnant, nursing, planning a pregnancy or who are of childbearing potential not using a reliable method of contraception.
• History or current evidence of hypersensitivity to any components of the study medication, as assessed by the investigator.
• Participation in any systemic experimental treatment or any other systemic investigational new drug within 6 weeks or 5 half-lives of the active ingredient (whichever is longer) prior to the start of study treatment. Clinical trials solely involving observation, over-the-counter vitamins, supplements, or diets are not exclusionary

Cohort 2

• Body weight less than 55 kg.
• Females who are pregnant, nursing, planning a pregnancy or who are of childbearing potential not using a reliable method of contraception.
• History or current evidence of hypersensitivity to any components of the study medication, as assessed by the investigator.
• Participation in any investigational drug or ocular device study within 30 days prior to the Day 1 Study Visit.
• History or current evidence of a medical condition that may, in the opinion of the investigator, preclude the safe administration of study medication or affect the results of the study.
• Participation in any systemic experimental treatment or any other systemic investigational new drug within 5 half-lives of the active ingredient prior to the start of study treatment. Clinical trials solely involving observation, over-the-counter vitamins, supplements, or diets are not exclusionary.
• History of use of teprotumumab (Tepezza), radiotherapy, or orbital surgery.
• History (last 6 weeks) of use of systemic immunosuppressants (e.g. mycophenolate), intravenous immunoglobulin, or plasmapheresis.
• Clinical activity score < 3
• Uncontrolled diabetes or hypertension
• History of mental / psychiatric disorder
• Hepatic dysfunction (Albumin (Alb), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline phosphates levels must be within normal range for eligibility)
• Renal impairment (Urea, Creatinine, and Glomerular Filtration Rate levels must be within normal range)
• Any baseline condition that the principal investigator considers exclusionary.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Inflammasome Therapeutics

UNKNOWN

Sponsor Role: collaborator

Peter Timoney

OTHER

Sponsor Role: lead

Responsible Party

Peter Timoney

Associate Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Peter Timoney

Role: PRINCIPAL_INVESTIGATOR

University of Kentucky

Locations

University of Kentucky

Lexington, Kentucky, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Connie Dampier

Role: CONTACT

dampier@email.uky.edu

859-562-0750

Facility Contacts

Connie Dampier

Role: primary

dampier@email.uky.edu

859-562-0750

Other Identifiers

94519

Identifier Type: -

Identifier Source: org_study_id